Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials

Xiafei Lyu, Xiaolin Zhu, Bin Zhao, Liang Du, Dawei Chen, Chun Wang, Guanjian Liu & Xingwu Ran

Dipeptidyl peptidase-4 (DPP-4) inhibitors are a novel family of glucose-lowering agents. Accumulating evidence suggests that DPP-4 inhibitors preserve pancreatic beta-cell function, but results in previous studies have been inconsistent. We assessed the effects of DPP-4 inhibitors on the homeostasis model assessment beta-cell function (HOMA-B) or insulin resistance (HOMA-IR) index in patients with type 2 diabetes through a systematic review and meta-analysis of randomized controlled trials (RCTs). Relevant articles were identified from PubMed, Embase, and Cochrane Library databases up to December 27, 2016. We calculated weighted mean differences (WMDs) and 95% confidence intervals (CIs) in each included trial and pooled the data using a random-effects model. Fifty-two trials were included in the present analysis. Compared with placebo control, DPP-4 inhibitors as monotherapy significantly improved HOMA-B (WMD 9.15; 95% CI 7.48, 10.81). Similarly, DPP-4 inhibitors as add-on therapy in combination with other drugs showed significant improvement in HOMA-B (WMD 9.04; 95% CI 5.72, 12.37). However, we found no significant improvement in HOMA-IR following treatment with DPP-4 inhibitors as mono-therapy or as add-on therapy. In conclusion, DPP-4 inhibitors as monotherapy or as add-on therapy significantly improved beta-cell function but had no significant effect on insulin resistance in type 2 diabetes.

Type 2 diabetes mellitus (T2DM) is characterized by a progressive decline in beta-cell function with insulin resistance. Beta-cell dysfunction and insulin resistance are the central mechanisms in the pathogenesis of T2DM. As a surrogate marker for measuring beta-cell function and insulin sensitivity, the homeostasis model assessment (HOMA) indexes, which are based on fasting glucose and insulin levels, have been widely used for decades in clinical and epidemiological research. The validity of HOMA indexes have been confirmed against the hyperglycemic and euglycemic clamps and the intravenous glucose tolerance test. Recently, the Whitehall II study has shown that beta-cell function and insulin sensitivity as measured by HOMA beta-cell function (HOMA-B) and HOMA insulin resistance (HOMA-IR) may undergo significant reduction several years before the diagnosis of T2DM. The UK Prospective Diabetes Study (UKPDS) has demonstrated that HOMA-B continues to deteriorate in association with progressively increasing hyperglycemia despite treatment. These data highlight the importance of preserving beta-cell function and insulin sensitivity in the prevention and management of T2DM.

Dipeptidyl peptidase-4 (DPP-4) inhibitors are a novel family of glucose-lowering agents that are increasingly used in clinical practice in treating T2DM patients. DPP-4 is responsible for the degradation of incretin

1 Diabetic Foot Care Center, West China Hospital, Sichuan University, Guoxue Lane No. 37, Chengdu, Sichuan, China. 2 Department of Radiology, West China Hospital, Sichuan University, Guoxue Lane No. 37, Chengdu, Sichuan, China. 3 Global Medical Affairs, Merck Sharp & Dohme China, Shanghai, China. 4 Chinese Evidence-Based Medicine Centre, Chinese Cochrane Center, West China Hospital, Sichuan University, Guoxue Lane No. 37, Chengdu, Sichuan, China. 5 Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Guoxue Lane No. 37, Chengdu, Sichuan, China. Correspondence and requests for materials should be addressed to X.R. (email: ranxingwu@163.com)
hormones such as glucagon-like peptide 1 (GLP-1)\(^8\). Inhibition of DPP-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in T2DM patients\(^8\). DPP-4 inhibitors have many favorable features including a low risk of hypoglycemia and a neutral effect on body weight\(^8\). In addition, they are efficacious and well tolerated as mono-therapy and also as add-on therapy in combination with commonly prescribed anti-diabetic agents and are suitable for once-daily oral dosing\(^8,10\). As a result, the American Diabetes Association and the European Association for the Study of Diabetes recommend DPP-4 inhibitors as part of a combination therapy with metformin and/or other agents or as a preferable monotherapy choice for patients in whom metformin is contraindicated or not tolerated\(^11,12\).

The underlying mechanisms of DPP-4 inhibitors in the management of T2DM remain to be understood, and the roles of DPP-4 inhibitors on beta-cell function and insulin sensitivity are of particular interest. Experimental data show that DPP-4 inhibitors may help preserve pancreatic beta-cell function\(^13,14\). However, results from previous studies in humans have been inconsistent, partly because of the limited sample size and insufficient statistical power in some individual studies. In this study, we aimed to systematically review the available evidence and quantitatively summarize the findings by performing a meta-analysis of randomized controlled trials (RCTs).

**Material and Methods**

This study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement\(^15\).

**Study selection.** Articles were eligible for inclusion if they fulfilled all the following criteria: (i) they were RCTs; (ii) the participants were patients with T2DM; (iii) they compared a DPP-4 inhibitor as monotherapy or add-on therapy with an appropriate control; (iv) they provided information on HOMA-estimated beta-cell function or insulin resistance; (v) the study duration was no less than 12 weeks; and (vi) the results were published in peer-reviewed journal as a full paper. We excluded the following types of articles: review articles or editorials, non-human studies (i.e., cell culture or animal studies), studies that did not include DPP-4 inhibitor treatment in the intervention group, and studies that did not evaluate beta-cell function or insulin resistance. Disagreement about eligibility was resolved by consensus between all authors.
Literature search. We performed a comprehensive literature search in the PubMed, EMBASE, and Cochrane Library databases. The last search update was conducted on up to December 27, 2016. In terms of the database search strategy, we used a combination of free text (e.g., type 2 diabetes) and subheadings from MeSH (e.g., “Diabetes Mellitus, Type 2” [Mesh]) or EMTREE terms (e.g., ‘non insulin dependent diabetes mellitus’/exp). In addition to using the generic term for DPP-4 inhibitors, we also specifically named each major DPP-4 inhibitor (e.g., Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Anagliptin, Teneligliptin, Alogliptin, Gemigliptin, and Dutogliptin) when conducting the literature search. More detailed search terms are listed in the Supplementary Materials. The reference lists of relevant studies and review articles were also checked to identify additional relevant studies.

Data extraction. The following data were extracted from each eligible article: the first author’s name, year of publication, sample size, participants’ age, T2DM duration, types of DPP-4 inhibitors tested, study duration, mean baseline HbA1c, and mean and standard deviation of HOMA indexes in the comparison groups. When necessary, we contacted the corresponding authors of the original articles by email to request relevant data or information. If multiple articles were published using data from the same study, we extracted the report with the information most relevant to the analysis. If the same trial reported data at different follow-up periods, we extracted the data corresponding to the longest follow-up period. If a study reported results on the effects of DPP-4 inhibitors at different doses, we extracted data corresponding to the standard dosages for each DPP-4 inhibitor (e.g., sitagliptin 100 mg/day; saxagliptin 5 mg/day; vildagliptin 100 mg/day; linagliptin 5 mg/day; teneligliptin 20 mg/day; and alogliptin 25 mg/day) unless otherwise specified.

Quality assessment of the included RCTs. Assessment of risk of bias in the included RCTs was performed according to the Cochrane Collaboration’s tool, which includes the following domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias. The risk of bias in each domain was assessed as low, high, or unclear.

Data synthesis and statistical analysis. We calculated weighted mean differences (WMDs) and 95% confidence intervals (CIs) for the change in HOMA indexes from baseline to the end of the trial for DPP-4 inhibitors versus controls reported in each of the included trials and pooled the data in the meta-analysis using a random-effects model. If both adjusted (typically derived from analysis of covariance) and unadjusted changes were reported in the same trial, we included both the adjusted and unadjusted findings in the meta-analysis. However, if the authors did not report the raw data used to calculate the adjusted or unadjusted effect size, we were unable to calculate these values and the data could not be included in the meta-analysis. The WMDs with 95% CIs were then calculated for each treatment arm. In cases where the results were not reported as WMDs with 95% CIs, we attempted to calculate the WMDs and 95% CIs using the reported data.

Figure 2. Effects of DPP-4 inhibitors as monotherapy (DPP-4 inhibitors versus placebo) on beta-cell function. WMD, weighted mean difference; CI, confidence interval.

| Author | Year | Intervention | Control | WMD (95% CI) |
|--------|------|--------------|---------|-------------|
| Ristic | 2005 | Vildagliptin 100 mg | Placebo | 26.84 (7.16, 46.52) |
| Aschner | 2006 | Sitagliptin 100 mg | Placebo | 12.90 (3.88, 21.92) |
| Pratley | 2006 | Vildagliptin 50 mg | Placebo | 10.20 (-2.58, 22.98) |
| Raz | 2006 | Sitagliptin 100 mg | Placebo | 11.10 (0.20, 22.00) |
| Goldstein | 2007 | Sitagliptin 100 mg | Placebo | 7.10 (0.01, 14.19) |
| Hanefeld | 2007 | Sitagliptin 100 mg | Placebo | 12.50 (1.33, 23.67) |
| Scott | 2007 | Sitagliptin 100 mg | Placebo | 17.90 (7.33, 28.47) |
| DeFranzo | 2008 | Alogliptin 25 mg | Placebo | 9.96 (-4.23, 24.15) |
| Nonaka | 2008 | Sitagliptin 100 mg | Placebo | 12.60 (7.79, 17.41) |
| Pratley | 2008 | Vildagliptin 50 mg | Placebo | 11.50 (2.94, 20.06) |
| Rosenstock | 2008 | Saxagliptin 5 mg | Placebo | 17.62 (-5.79, 41.03) |
| Mohan | 2009 | Sitagliptin 100 mg | Placebo | 5.40 (-1.62, 12.42) |
| Rosenstock | 2009 | Saxagliptin 5 mg | Placebo | 5.17 (-3.92, 14.26) |
| Rhee | 2010 | Gemigliptin 50 mg | Placebo | 23.05 (7.61, 38.49) |
| Del Prato | 2011 | Linagliptin 5 mg | Placebo | 22.20 (-0.05, 44.45) |
| Selin | 2011 | Alogliptin 25 mg | Placebo | 8.04 (4.47, 11.61) |
| Kawamori | 2012 | Linagliptin 5 mg | Placebo | 2.14 (-8.07, 12.35) |
| Kutoh | 2012 | Alogliptin 25 mg | Diet | 4.59 (-2.02, 11.20) |
| Pan | 2012 | Saxagliptin 5 mg | Placebo | 6.70 (1.35, 12.05) |
| Kadowaki | 2013 | Teneligliptin 20 mg | Placebo | 8.20 (4.32, 12.08) |
| Fukui | 2015 | Sitagliptin 50 mg | Sulfonylureas | 27.90 (-10.02, 65.82) |
| Jung | 2015 | Evogliptin 5 mg | Placebo | 15.00 (0.44, 29.56) |
| Yokoh | 2015 | Sitagliptin 50 mg | AGIs | 9.50 (-1.13, 20.13) |
| Overall (I² = 3.8%, p = 0.409) | | | | 9.15 (7.48, 10.81) |

NOTE: Weights are from random effects analysis.
| Author, year | Study design | Intervention | Control | No. of subjects (Int/Ctrl) | Mean age (years) | Mean BMI (kg/m²) | Mean T2DM duration (years) | Mean baseline HbA1c | Study duration (weeks) |
|-------------|--------------|--------------|---------|----------------------------|-----------------|-----------------|----------------------------|-------------------|----------------------|
| Ristic et al. | Monotherapy | Vildagliptin 100 mg | Placebo | 53/58 | 55.0 | 31.4 | 2.7 | 7.7 | 12 |
| Aschner et al. | Monotherapy | Sitagliptin 100 mg | Placebo | 238/253 | 54.0 | 30.5 | 4.5 | 8.0 | 24 |
| Charbonnel et al. | Add-ons | Sitagliptin 100 mg + Metformin | Placebo + Metformin | 464/237 | 54.5 | 31.0 | 6.3 | 8.0 | 24 |
| Pratley et al. | Monotherapy | Vildagliptin 50 mg | Placebo | 70/28 | 54.0 | 30.0 | 4.0 | 8.1 | 12 |
| Raz et al. | Monotherapy | Sitagliptin 100 mg | Placebo | 205/110 | 55.5 | 32.0 | 4.6 | 8.0 | 18 |
| Rosenstock et al. | Add-ons | Sitagliptin 100 mg + Pioglitazone | Placebo + Pioglitazone | 175/178 | 56.0 | 31.5 | 6.1 | 8.0 | 24 |
| Goldstein et al. | Monotherapy | Sitagliptin 100 mg | Placebo | 179/176 | 53.4 | 32.0 | 4.5 | 8.8 | 24 |
| Hanefeld et al. | Monotherapy | Sitagliptin 100 mg | Placebo | 110/111 | 56.0 | 31.5 | 3.5 | 7.7 | 12 |
| Hermansen et al. | Add-ons | Sitagliptin 100 mg + Glimepiride ± Metformin | Placebo + Glimepiride ± Metformin | 222/219 | 55.0 | 31.0 | 8.8 | 8.3 | 24 |
| Scott et al. | Monotherapy | Sitagliptin 100 mg | Placebo | 124/125 | 55.2 | 31.0 | 4.5 | 9.5 | 12 |
| DeFronzo et al. | Monotherapy | Alogliptin 25 mg | Placebo | 131/64 | 53.4 | NR | NR | 7.9 | 26 |
| Nonaka et al. | Monotherapy | Sitagliptin 100 mg | Placebo | 57/57 | 55.3 | 25.0 | 4.0 | 8.0 | 24 |
| Pratley et al. | Monotherapy | Vildagliptin 100 mg | Placebo | 1470/182 | 53.0 | 32.3 | 2.2 | 8.5 | 24 |
| Raz et al. | Add-ons | Sitagliptin 100 mg + Metformin | Placebo + Metformin | 94/94 | 55.3 | 30.0 | 5.2 | 8.0 | 18 |
| Pratley et al. | Monotherapy | Saxagliptin 5 mg | Metformin | 253/267 | 55.0 | 29.0 | 6.8 | 8.4 | 24 |
| Rhee et al. | Add-ons | Saxagliptin 5 mg + Glyburide | Placebo + Glyburide | 191/179 | 54.8 | 31.4 | 6.5 | 8.1 | 24 |
| Williams-Herman et al. | Add-ons | Saxagliptin 5 mg + Thiazolidinediones | Thiazolidinediones | 186/184 | 53.6 | 30.0 | 5.2 | 8.3 | 24 |
| Mohan et al. | Monotherapy | Sitagliptin 100 mg | Placebo | 352/178 | 50.0 | 25.0 | 2.0 | 8.8 | 18 |
| Rosenstock et al. | Monotherapy | Saxagliptin 5 mg | Placebo | 106/95 | 54.0 | 31.0 | 2.4 | 8.0 | 12 |
| Forst et al. | Add-ons | Linagliptin 5 mg + Metformin | Metformin | 66/71 | 60.0 | 32.0 | 6.8 | 8.5 | 12 |
| Rhee et al. | Monotherapy | Gemigliptin 50 mg | Placebo | 35/34 | 52.0 | 25.3 | 4.4 | 8.2 | 12 |
| Williams-Herman et al. | Add-ons | Sitagliptin 100 mg + Metformin | Placebo + Metformin | 107/88 | 54.0 | 31.5 | 4.2 | 8.7 | 104 |
| Bosi et al. | Add-ons | Alogliptin 25 mg + Metformin + Pioglitazone | Metformin + Pioglitazone | 404/399 | 55.0 | 31.5 | 7.0 | 8.1 | 52 |
| Del Prato et al. | Monotherapy | Linagliptin 5 mg | Placebo | 336/167 | 55.0 | 29.1 | NR | 8.0 | 24 |
| Gomis et al. | Add-ons | Linagliptin 5 mg + Pioglitazone | Pioglitazone | 259/130 | 57.4 | 29.0 | NR | 8.6 | 24 |
| Kaku et al. | Add-ons | Alogliptin 25 mg + Pioglitazone | Placebo + Pioglitazone | 113/115 | 60.0 | 26.3 | 6.8 | 7.9 | 12 |
| Owens et al. | Add-ons | Linagliptin 5 mg + Metformin + Sulphonylurea | Metformin + Sulphonylurea | 541/175 | 58.0 | 28.0 | NR | 8.1 | 24 |
| Reasner et al. | Add-ons | Sitagliptin 100 mg + Metformin | Metformin | 625/621 | 50.0 | 33.0 | 3.4 | 9.9 | 18 |
| Seino et al. | Add-ons | Alogliptin 25 mg + Voglibose | Voglibose | 79/75 | 62.5 | 24.0 | 8.0 | 8.0 | 12 |
| Seino et al. | Monotherapy | Alogliptin 25 mg | Placebo | 80/75 | 59.3 | 24.5 | 6.9 | 7.9 | 12 |
| Taskinen et al. | Add-ons | Linagliptin 5 mg + Metformin | Metformin | 523/177 | 56.6 | 30.0 | NR | 8.1 | 24 |
| Yoon et al. | Add-ons | Sitagliptin 100 mg + Pioglitazone | Pioglitazone | 261/259 | 51.0 | 29.7 | 2.4 | 9.5 | 24 |
| Kawamori et al. | Monotherapy | Linagliptin 5 mg | Placebo | 159/80 | 60.0 | 24.5 | NR | 8.0 | 12 |
| Kutoh et al. | Monotherapy | Alogliptin 25 mg | Diet | 25/26 | 48.0 | 26.3 | 0 | 10.3 | 12 |
| Pan et al. | Monotherapy | Saxagliptin 5 mg | Placebo | 284/284 | 51.4 | 25.9 | 1.0 | 8.1 | 24 |
| Seino et al. | Add-ons | Alogliptin 25 mg + Metformin | Metformin | 96/100 | 52.2 | 25.0 | 6.3 | 8.0 | 12 |

Continued
from baseline were reported in a trial, we selected the adjusted estimates as they accounted for possible baseline imbalance and the correlation between baseline and follow-up measures. When the adjusted estimates were not available, we limited meta-analyses to those trials with baseline balance in HOMA indexes. When standard deviations of the change from baseline were not reported in the article, we converted standard errors or 95% CIs to standard deviations.

We used forest plots to visualize the effect sizes in each individual study and the pooled overall effect size. We assessed between-study heterogeneity using the $\chi^2$-based Cochrane’s Q statistic and the $I^2$ metric ($I^2$ values of 25%, 50%, and 75% were considered to indicate low, medium, and high heterogeneity, respectively). Potential publication bias is assessed by funnel plots, in which asymmetrical plot indicates presence of reporting bias.

To explore the possible differences in the effectiveness of individual DPP-4 inhibitors on beta-cell function and insulin sensitivity, we performed stratification analysis according to the type of DPP-4 inhibitor tested. Sensitivity analyses were performed by omitting one study at a time and computing the pooled effect size of the remaining studies to evaluate whether the results were affected markedly by a single study. All statistical analyses were performed using Stata software version 11.0 (Stata Corp, College Station, TX, USA).

### Results

**Characteristics of the included studies.** We identified 589 potentially relevant articles from database search and other resources. After screening, 278 articles were evaluated in detail and 52 articles presenting RCTs were finally included in the meta-analysis (Fig. 1). Of them, 23 articles reported data from trials using DPP-4 inhibitors as monotherapy, 28 articles from trials using DPP-4 inhibitors as add-on therapy, and the other one article involving mixed study design using DPP-4 inhibitors as both monotherapy and add-on therapy.

The baseline characteristics of the included RCTs in the meta-analysis are shown in Table 1. The majority of studies were conducted in Caucasian or Asian populations. Sitagliptin was the most investigated drug among DPP-4 inhibitors as monotherapy and add-on therapy in the included studies. Most of the included RCTs had a relatively short study duration (typically 12 or 24 weeks). The risk of bias varied across the individual trials. All the included trials, except one, involved appropriate double blind procedures, and none were associated with concerns about selective outcome reporting. However, in some of the included trials, HOMA-IR or HOMA-B data were missing for more than 20% of the participants, because these indicators were not the primary outcome and therefore were not assessed all participants. In addition, information regarding random generation sequence, allocation concealment, and blinding of outcome assessment was not clearly described in most trials (Supplementary Table 1).

| Author, year | Study design | Intervention | Control | No. of subjects (Int/Ctrl) | Mean age (years) | Mean BMI (kg/m²) | Mean T2DM duration (years) | Mean baseline HbA1c | Mean T2DM duration (weeks) |
|--------------|--------------|--------------|---------|----------------------------|-----------------|-----------------|---------------------------|----------------|--------------------------|
| Dobs et al.18 | Add-ons      | Sitagliptin 100 mg + Metformin + rosiglitazone | Metformin + rosiglitazone | 170/92                  | 54.6            | 30.5            | 9.3                        | 8.8            | 54                       |
| Kadowaki et al.20 | Monotherapy | Teneligliptin 20 mg | Placebo | 79/80                    | 58.8            | 25.1            | 6.0                        | 7.9            | 12                       |
| Zeng et al.22 | Add-ons      | Linagliptin 5 mg + Metformin + Sulphonylurea | Placebo + Metformin + Sulphonylurea | 144/48              | 56.0            | 25.8            | NR                        | 8.1            | 12                       |
| Heise et al.24 | Mixed        | Linagliptin 5 mg + Various anti-diabetic medications | Placebo + Various anti-diabetic medications | 1905/796         | 57.0            | 29.3            | NR                        | 8.2            | 24                       |
| Yokoyama et al.25 | Add-ons | Sitagliptin 100 mg + Sulfonylureas | Sulfonylureas | 49/50                     | 61.3            | 25.9            | 11.3                       | 7.8            | 24                       |
| Fukui et al.26 | Monotherapy | Sitagliptin 50 mg | 21/22  | 66.3            | 26.3            | 7.5            | 7.3                        | 24                       |
| Jung et al.27 | Monotherapy | Evogliptin (DA1229) 5 mg | Placebo | 43/48                    | 54.3            | 25.5            | 3.7                        | 7.6            | 12                       |
| Leibowitz et al.28 | Add-ons | Saxagliptin 5 mg + Various anti-diabetic medications | Placebo + Various anti-diabetic medications | 2408/2312         | 65.2            | 31.1            | 8.3                        | 7.5            | 151                      |
| Strozek et al.29 | Add-ons      | Vildagliptin 100 mg + Metformin | Metformin | 17/16                     | 55.0            | 32.0            | NR                        | 8.1            | 12                       |
| Yokoh et al.30 | Monotherapy | Sitagliptin 50 mg | Alpha-glucosidase inhibitor | 58/58                   | 58.5            | 26.1            | 6.8                        | 7.6            | 24                       |
| Zografou et al.31 | Add-ons | Vildagliptin 50 mg + Metformin | Metformin | 32/32                     | 54.4            | 31.9            | NR                        | 8.1            | 24                       |
| Ba et al.32 | Add-ons      | Sitagliptin 100 mg + Sulfonylureas ± Metformin | Placebo + Sulfonylureas ± Metformin | 249/249              | 56.0            | 25.4            | 7.0                        | 8.5            | 24                       |
| Ekholm et al.33 | Add-ons      | Saxagliptin 5 mg + Dapagliflozin + Metformin | Placebo + Dapagliflozin + Metformin | 160/152            | 54.0            | 32              | 7.3                        | 8.9            | 24                       |
| Oyama et al.34 | Add-ons      | Sitagliptin 25–100 mg + Conventional therapy | Conventional therapy | 222/220                  | 69.3            | 25.1            | NR                        | 7.0            | 24                       |

Table 1. Characteristics of the RCTs included in the meta-analysis. Abbreviations: Int, intervention group; Ctrl, control group; BMI, body mass index; T2DM, type 2 diabetes mellitus; HbA1c, hemoglobin A1c; NR, not reported.
Effects of DPP-4 inhibitors as monotherapy on beta-cell function and insulin resistance. Our meta-analysis of 23 RCTs showed that DPP-4 inhibitors as monotherapy significantly improved beta-cell function (Fig. 2). The pooled WMD (95% CI) for the HOMA-B was 9.15 (7.48, 10.81). We observed no evidence for significant heterogeneity ($I^2 = 4\%$, $P = 0.41$). For insulin resistance, we found no significant improvement after treatment with DPP-4 inhibitors as monotherapy (Fig. 3). Sensitivity analyses conducted by omitting one study at a time did not show significant alteration of the results.

Effects of DPP-4 inhibitors as add-on therapy on beta-cell function and insulin resistance. In a meta-analysis of 28 RCTs, we found that treatment with DPP-4 inhibitors as add-on therapy in combination with other drugs significantly improved beta-cell function (Fig. 4). The pooled WMD (95% CI) for the HOMA-B was 9.04 (5.72, 12.37). There was evidence for significant heterogeneity ($I^2 = 89\%$, $P < 0.001$). Similar to the findings for DPP-4 inhibitor monotherapy, we found no significant improvement in insulin resistance after treatment with DPP-4 inhibitors as monotherapy (Fig. 3). Sensitivity analyses conducted by omitting one study at a time did not show significant alteration of the results.

Publication bias. In the funnel plots, we observed evidence of publication bias (i.e., asymmetrical plots) in the meta-analysis of DPP-4 inhibitors as either monotherapy (Supplementary Figures 1 and 2) or add-on therapy (Supplementary Figures 3 and 4) on beta-cell function and insulin resistance. However, these results should be interpreted with caution, because asymmetrical plots may also be a result of other reasons, such as small study effects, rather than publication bias.

Comparative effects of individual DPP-4 inhibitors as monotherapy. In stratification analyses according to the types of DPP-4 inhibitors, we pooled data for each DPP-4 inhibitor. We found that treatment with all types of DPP-4 inhibitors except for linagliptin resulted in an increase in HOMA-B (Supplementary Figure 5). In the meta-analysis of the effects of individual DPP-4 inhibitors on insulin resistance (Supplementary Figure 6), we observed a significant improvement in insulin resistance with sitagliptin treatment without evidence of significant heterogeneity ($\text{WMD} = -0.38; 95\% \text{ CI} = -0.69, -0.08; I^2 = 0\%$, $P$ for heterogeneity = 0.58). Linagliptin seemed to have a trend to increase insulin resistance, but the results should be interpreted cautiously due to the limited number of available studies. We found no significant effects of other DPP-4 inhibitors on insulin resistance.

| Author      | Year | Intervention   | Control  | WMD (95% CI) |
|-------------|------|---------------|----------|--------------|
| Ristic      | 2005 | Vildagliptin 100 mg | Placebo  | 0.46 (-0.93, 1.85) |
| Pratley     | 2006 | Vildagliptin 50 mg  | Placebo  | 0.51 (-1.44, 2.46)  |
| Goldstein   | 2007 | Sitagliptin 100 mg  | Placebo  | -0.50 (-1.38, 0.38) |
| Hanefeld    | 2007 | Sitagliptin 100 mg  | Placebo  | -0.40 (-1.74, 0.94) |
| Scott       | 2007 | Sitagliptin 100 mg  | Placebo  | -0.20 (-1.40, 1.00) |
| Nonaka      | 2008 | Sitagliptin 100 mg  | Placebo  | -0.24 (-0.63, 0.15) |
| Pratley     | 2008 | Vildagliptin 100 mg | Placebo  | -8.50 (-13.89, -3.11) |
| Mohan       | 2009 | Sitagliptin 100 mg  | Placebo  | -1.00 (-1.82, -0.18) |
| Rosenstock  | 2009 | Saxagliptin 5 mg   | Placebo  | 0.01 (-0.39, 0.41)  |
| Rhee        | 2010 | Gemigliptin 50 mg   | Placebo  | -0.24 (-1.12, 0.64) |
| Del Prato   | 2011 | Linagliptin 5 mg    | Placebo  | 0.20 (-0.94, 1.34)  |
| Seino       | 2011 | Alogliptin 25 mg    | Placebo  | -0.02 (-0.39, 0.35) |
| Kawamori    | 2012 | Linagliptin 5 mg    | Placebo  | 0.36 (0.17, 0.55)   |
| Kuroh       | 2012 | Alogliptin 25 mg    | Diet     | 1.03 (-0.32, 2.38)  |
| Kadowaki    | 2013 | Teneligliptin 20 mg | Placebo  | 0.00 (-0.28, 0.28)  |
| Jung        | 2015 | Evogliptin 5 mg     | Placebo  | 0.26 (-0.81, 1.33)  |
| Yokoh       | 2015 | Sitagliptin 50 mg   | AGIs     | -0.26 (-1.55, 1.03) |
| Overall     |      | (I-squared = 51.9%, $p = 0.007$) |         | -0.04 (-0.28, 0.19) |

NOTE: Weights are from random effects analysis

Figure 3. Effects of DPP-4 inhibitors (monotherapy versus placebo) on insulin resistance. WMD, weighted mean difference; CI, confidence interval.
Figure 4. Effects of DPP-4 inhibitors as add-on therapy (DPP-4 inhibitors + other drugs versus placebo + the same other drugs) on beta-cell function. WMD, weighted mean difference; CI, confidence interval.

Figure 5. Effects of DPP-4 inhibitors as add-on therapy (DPP-4 inhibitors + other drugs versus placebo + the same other drugs) on insulin resistance. WMD, weighted mean difference; CI, confidence interval.
Discussion

Our meta-analysis of data from 52 RCTs showed that DPP-4 inhibitors as monotherapy or as add-on therapy significantly improved beta-cell function as measured by the HOMA-B. However, there was no significant improvement in insulin resistance with the use of DPP-4 inhibitors as monotherapy or as add-on therapy in combination with other drugs. Consistent with the results of previous meta-analyses, these findings provide important insight into the pathophysiologic mechanisms of DPP-4 inhibitor action in the treatment of T2DM.

Our results regarding the effects of DPP-4 inhibitor treatment on beta-cell function were largely consistent with results from the largest trials using DPP-4 inhibitors as monotherapy, adds-on therapy, or mixed trial design involving multiple trials. In the trial by Pratley et al., vildagliptin monotherapy yielded consistently robust improvement in beta-cell function, measured not only by HOMA-B based on fasting glucose and insulin but also by meal test-derived measures, across a broad spectrum of drug-naïve patients with T2DM. In addition, our findings were consistent with those of other studies that measured dynamic beta-cell function after meal ingestion. For instance, in a meal tolerance test performed with a double tracer technique (3-(3)H-glucose iv and 1-(14)C-glucose orally), the DPP-4 inhibitor vildagliptin significantly increased the insulin secretion rate divided by plasma glucose by 29% in T2DM patients. When added to metformin therapy in patients with T2DM, vildagliptin treatment resulted in a significant increase in insulin secretion (postmeal supra basal area under the 0–30 min C-peptide curve divided by the 30-min increase in glucose).

The favorable effects of DPP-4 inhibitors for improving beta-cell function among patients with T2DM are biologically plausible. DPP-4 inhibitor treatment in diabetic animal models stimulated beta-cell survival, facilitated islet neogenesis, enhanced insulin biosynthesis, and preserved beta-cell mass and function. Moreover, DPP-4 gene knockout mice showed better insulin sensitivity and less pancreatic islet hypertrophy and were resistant to streptozotocin-induced loss of beta-cell mass and hyperglycemia. In humans with T2DM, DPP-4 inhibitors have demonstrated improvement of beta-cell function both in the fasting and postprandial statuses, and these beneficial effects were sustained in studies with a duration up to 2 years. DPP-4 inhibitors may restore beta-cell function and survival in isolated human islets through glucagon-like peptide (GLP)-1 stabilization. Recently, it is reported that DPP-4 inhibitors may exert an anti-inflammatory effect, which may alleviate the loss of beta-cell function. Interestingly, our meta-analysis showed that sitagliptin, but not the other tested DPP-4 inhibitors, as monotherapy resulted in significant improvement in insulin resistance. This finding needs to be confirmed in future studies.

The study has strengths in that it was conducted using a systematic approach and the results are based on a large number of published RCTs. However, there are several limitations. First, most of the included studies had a follow-up duration of less than 6 months. The longer-term effects of DPP-4 inhibitor treatment on beta-cell function and insulin resistance in patients with T2DM warrant further investigation. Second, our study had a lack of power to compare the effectiveness of DPP-4 inhibitors in this study, because the number of available trials for some individual DPP-4 inhibitors was still limited. DPP-4 inhibitors have similar but still varying pharmacological features and, thus, their effects on beta-cell function and insulin resistance may vary. Third, we used the HOMA-B as the indicator of beta-cell function. Because this parameter is originally estimated based on fasting glucose and insulin levels, it may not sufficiently represent postprandial beta-cell function. Fourth, publication bias may exist regarding the effects of DPP-4 inhibitors on beta-cell function.

In conclusion, among patients with T2DM, DPP-4 inhibitors as monotherapy or as add-on therapy in combination with other drugs significantly improved beta-cell function but had no significant effect on insulin resistance.

References

1. Kahn, S. E. Clinical review 135: The importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 86, 4047–58 (2001).
2. Fonseca, V. A. Defining and characterizing the progression of type 2 diabetes. Diabetes Care 32 Suppl 2, S151–6 (2009).
3. Halban, P. A. et al. Beta-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. Diabetes Care 37, 1751–8 (2014).
4. Matthews, D. R. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412–9 (1985).
5. Wallace, T. M., Levy, J. C. & Matthews, D. R. Use and abuse of HOMA modeling. Diabetes Care 27, 1487–95 (2004).
6. Tabak, A. G. et al. Trajectories of glycemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 373, 2215–21 (2009).
7. Cnop, M. et al. Progressive loss of beta-cell function leads to worsening glucose tolerance in first-degree relatives of subjects with type 2 diabetes. Diabetes Care 30, 677–82 (2007).
8. Barnett, A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 60, 1454–70 (2006).
9. Ahren, B. et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89, 2078–84 (2004).
10. Dicker, D. DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors. Diabetes Care 34 Suppl 2, S276–8 (2011).
11. Inzucchi, S. E. et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38, 140–9 (2015).
12. Inzucchi, S. E. et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35, 1364–79 (2012).
13. Mu, J. et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. *Diabetes* **55**, 1695–704 (2006).

14. Mu, J. et al. Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes. *Eur J Pharmacol* **623**, 148–54 (2009).

15. Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G. & Group, P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ* **339**, b2535 (2009).

16. Goldstein, B. J. et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. *Diabetes Care* **30**, 1979–87 (2007).

17. Williams-Herman, D. et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. *Curr Med Res Opin* **25**, 569–83 (2009).

18. Williams-Herman, D. et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. *Diabetes Obes Metab* **12**, 462–46 (2010).

19. Higgins, J. P. T. et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. *BMJ* **343**, D928 (2011).

20. DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. *Control Clin Trials* **7**, 177–88 (1986).

21. Riley, R. D. et al. Meta-analysis of randomised trials with a continuous outcome according to baseline imbalance and availability of individual participant data. *Stat Med* **32**, 2747–66 (2013).

22. Higgins, J. P., Thompson, S. G., Deeks, J. J. & Altman, D. G. Measuring inconsistency in meta-analyses. *BMJ* **337**, 557–60 (2003).

23. Ristic, S., Byiers, S., Foley, J. & Holmes, D. Improved glycemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. *Diabetes Obes Metab* **7**, 692–8 (2005).

24. Aschner, P. et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. *Diabetes Care* **29**, 2632–7 (2006).

25. Charbonnel, R., Karasik, A., Liu, J., Wu, M. & Meiningr, G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. *Diabetes Care* **29**, 2638–43 (2006).

26. Pratley, R. E., Jaufret-Kamel, S., Galbreath, E. & Holmes, D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. *Horm Med Res** **38**, 423–8 (2006).

27. Raz, I. et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. *Diabetologia* **49**, 756–71 (2006).

28. Rosenstock, J., Brazg, R., Andryuk, P. J., Lu, K. & Stein, P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. *Clin Ther* **29**, 1536–68 (2007).

29. Rogers, J. M. et al. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. *Curr Med Res Opin* **23**, 1329–39 (2007).

30. Hermansen, K. et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. *Diabetes Obes Metab* **9**, 733–45 (2007).

31. Scott, R., Wu, M., Sanchez, M. & Stein, P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. *Int J Clin Pract* **61**, 171–80 (2007).

32. DeFrancesco, R. A., Fleck, P. R., Wilson, C. A., Mekki, Q. & Alogliptin Study, G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. *Diabetes Care* **31**, 2315–7 (2008).

33. Nonaka, K. et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. *Diabetes Res Clin Pract* **79**, 291–8 (2008).

34. Pratley, R. E. et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naive patients: analysis of pooled vildagliptin monotherapy database. *Diabetes Obes Metab* **10**, 931–8 (2008).

35. Raz, I. et al. Efficacy and safety of alogliptin added to ongoing metformin therapy in patients with type 2 diabetes. *Curr Med Res Opin* **24**, 557–50 (2008).

36. Rosenstock, J., Jankowski, S., List, J. F. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. *Diabetes Obes Metab* **10**, 376–86 (2008).

37. Scott, R., Loeyes, T., Davies, M. J., Engel, S. S. & Sitagliptin Study, G. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. *Diabetes Obes Metab** **10**, 959–69 (2008).

38. Chacra, A. R. et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with up titration of sulphonylurea in patients with type 2 diabetes: a randomised controlled study. *Clin Pract* **63**, 1395–406 (2009).

39. DeFrancesco, R. A. et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. *Diabetes Care* **32**, 1649–55 (2009).

40. Holland, P. L., Li, J. Allen, E. & Chen, R. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinediones alone. *J Endocrinol Metab* **94**, 4810–9 (2009).

41. Mohan, V. et al. Efficacy and safety of saxagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. *Diabetes Res Clin Pract* **83**, 106–16 (2009).

42. Rosenstock, J. et al. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. *Curr Med Res Opin* **25**, 2401–11 (2009).

43. Forst, T. et al. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with type 2 diabetes inadequately controlled. *Diabetes Metab** **27**, 1409–19 (2010).

44. Rhee, E. J. et al. A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes. *Diabetes Metab* **12**, 1113–9 (2010).

45. Bosi, E., Ellis, G. C., Wilson, C. A. & Fleck, P. R. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. *Diabetes Obes Metab** **13**, 1088–96 (2011).

46. Del Prato, S. et al. Effect of linagliptin monotherapy on glycemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. *Diabetes Obes Metab** **13**, 258–67 (2011).

47. Gomis, R., Espadero, R. M., Jones, R., Weeke, H. J. & Dugi, K. A. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. *Diabetes Obes Metab** **13**, 653–61 (2011).

48. Kaku, K., Itagaya, T., Hiroi, S., Hirayama, M. & Seino, Y. Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a 24-week randomized study. *Diabetes Obes Metab** **13**, 644–52 (2011).
51. Seino, Y., Fujita, T., Hiroi, S., Hirayama, M. & Kaku, K. Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension. *Curr Med Res Opin* **27** Suppl 3, 21–9 (2011).

52. Seino, Y., Fujita, T., Hiroi, S., Hirayama, M. & Kaku, K. Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study. *Curr Med Res Opin* **27**, 1781–92 (2011).

53. Taskinen, M. R. *et al.* Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. *Diabetes Obes Metab* **13**, 65–74 (2011).

54. Yoon, K. H. *et al.* Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of beta-cell function in patients with type 2 diabetes. *Int J Clin Pract* **65**, 154–64 (2011).

55. Kawamori, R. *et al.* Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study. *Diabetes Obes Metab* **14**, 348–57 (2012).

56. Kutoe, E. & Ukai, Y. Alogliptin as an initial therapy in patients with newly diagnosed, drug naïve type 2 diabetes: a randomized, control trial. *Endocrine* **41**, 435–41 (2011).

57. Pan, C. Y., Yang, W., Tou, C., Cause-Nilsen, I. & Zhao, J. Efficacy and safety of saxagliptin in drug-naive Asian patients with type 2 diabetes mellitus: a randomized controlled trial. *Diabetes Metab Res Rev* **28**, 268–75 (2012).

58. Seino, Y., Miyata, Y., Hiroi, S., Hirayama, M. & Kaku, K. Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study. *Diabetes Obes Metab* **14**, 927–36 (2012).

59. Dobs, A. S. *et al.* Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes. *J Diabetes* **5**, 68–79 (2013).

60. Kadowaki, T. & Kondo, K. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. *Diabetes Obes Metab* **15**, 810–8 (2013).

61. Zeng, Z. *et al.* Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised clinical trial. *Curr Med Res Opin* **29**, 921–9 (2013).

62. Heise, T. *et al.* The dipeptidyl peptidase-4 inhibitor linagliptin lowers postprandial glucose and improves measures of beta-cell function in type 2 diabetes. *Diabetes Obes Metab* **16**, 1036–9 (2014).

63. Yokoyama, H. *et al.* Liraglutide Versus Sitagliptin in a 24-week, Multicenter, Open-label, Randomized, Parallel-group Study in Japanese Type 2 Diabetes Mellitus Patients Responding Inadequately to a Sulfonylurea and/or One or Two Other Oral Antidiabetic Drugs (IDDIM 33). *Iop Clin Med* **5**, 33–41 (2014).

64. Fukui, K. *et al.* Dipeptidyl peptidase-4 inhibitor sitagliptin improves pancreatic beta-cell function in hypertensive diabetic patients treated with angiotensin receptor blockers. *J Renin Angiotensin Aldosterone Syst* **16**, 1001–9 (2015).

65. Jung, C. H. *et al.* A randomized, double-blind, placebo-controlled, phase II clinical trial to investigate the efficacy and safety of oral DA-1229 in patients with type 2 diabetes mellitus who have inadequate glycaemic control with diet and exercise. *Diabetes Metab Res Rev* **31**, 295–306 (2015).

66. Leibowitz, G. *et al.* Impact of treatment with saxagliptin on glycaemic stability and beta-cell function in the SAVOR-TIMI 53 study. *Diabetes Obes Metab** **17**, 487–94 (2015).

67. Strozik, A., Steplosz, A., Basiai, M., Drozdz, M. & Okopien, B. Multifactorial effects of vildagliptin added to ongoing metformin therapy in patients with type 2 diabetes mellitus. *Pharmacol Rep* **67**, 24–31 (2015).

68. Yokoh, H. *et al.* Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin-1): A multicenter, randomized, open-label, non-inferiority trial. *J Diabetes Investig* **6**, 182–91 (2015).

69. Zografou, I. *et al.* Effect of vildagliptin on hsCRP and arterial stiffness in patients with type 2 diabetes mellitus. *Hormones (Athens)* **14**, 118–25 (2015).

70. Ba, J. *et al.* Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin. *J Diabetes (Aug 8, 2016), doi: 10.1111/1753-0407.12456.

71. Ekholm, E. *et al.* Combined treatment with saxagliptin plus dapagliflozin reduces insulin levels by increased insulin clearance and improves beta-cell function. *Endocr Pract (Nov 16, 2016).

72. Oyama, J. *et al.* The Effect of Sitagliptin on Carotid Artery Atherosclerosis in Type 2 Diabetes: The PROLOGUE Randomized Controlled Trial. *PLoS Med* **11**, e1002051. (2016).

73. Riche, D. M., East, H. E. & Riche, K. D. Impact of sitagliptin on markers of beta-cell function: a meta-analysis. *Am J Med Sci* **337**, 321–8 (2009).

74. Lu, J., Zang, J. & Li, H. Impact of three oral antidiabetic drugs on markers of beta-cell function in patients with type 2 diabetes: a meta-analysis. *PLOS One* **6**, e76713 (2013).

75. Pratley, R. E. *et al.* Robust improvements in fasting and prandial measures of (beta-)cell function with vildagliptin in drug-naive patients: Analysis of pooled vildagliptin monotherapy database. *Diabetes, Obesity and Metabolism* **10**, 931–8 (2008).

76. Balas, B. *et al.* The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. *J Clin Endocrinol Metab* **92**, 1249–55 (2007).

77. Ahren, B., Pacini, G., Foley, J. E. & Schweizer, A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. *Diabetes Care* **28**, 1936–40 (2005).

78. van Genugten, R. E., van Raalte, D. H. & Diamant, M. Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell stabilization. *J Clin Endocrinol Metab* **98**, E1163–72 (2013).

79. Makdissi, A. *et al.* Sitagliptin exerts an antiinflammatory action. *J Clin Endocrinol Metab* **97**, 3333–41 (2012).

80. Omar, R. A. *et al.* Enhanced beta cell function and anti-inflammator action with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model. *Diabetologia* **56**, 1572–60 (2013).

81. Donath, M. Y. *et al.* Islet inflammation in type 2 diabetes: from metabolic stress to therapy. *Diabetes Care* **31** Suppl 2, S161–4 (2008).

82. Ma, D., Yu, Y., Yu, X., Zhang, M. & Yang, Y. The changes of leukocyte telomere length and telomerase activity after sitagliptin intervention in newly diagnosed type 2 diabetes. *Diabetes Metab Res Rev* **31**, 256–61 (2015).

83. Deacon, C. F. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. *Diabetes Obes Metab* **13**, 7–18 (2011).

84. Baetta, R. & Corsini, A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. *Drugs* **71**, 1441–67 (2011).
Acknowledgements
The study was supported by Merck & Co., Inc.

Author Contributions
L.X.F. and R.X.W. designed the study, conducted all searches, appraised all potential studies and wrote and revised the draft manuscript and subsequent manuscripts. Z.X.L. and Z.B. revised the draft manuscript and subsequent manuscripts. D.L. and C.D.W. assisted with the presentation of findings and assisted with drafting and revising the manuscript. W.C. and L.G.J. conceived and designed the study, assisted with searches, appraised relevant studies and assisted with drafting and revising the manuscript. All authors read and approved the final manuscript.

Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep

Competing Interests: The authors declare no competing financial interests.

How to cite this article: Lyu, X. et al. Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials. Sci. Rep. 7, 44865; doi: 10.1038/srep44865 (2017).

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2017